Arcadia Investment Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.62M | Sell |
26,704
-2,090
| -7% | -$122K | 0.28% | 59 |
|
|
2025
Q4 | $1.55M | Buy |
28,794
+1,380
| +5% | +$66.4K | 0.25% | 59 |
|
|
2025
Q3 | $1.24M | Buy |
27,414
+3,475
| +15% | +$162K | 0.19% | 64 |
|
|
2025
Q2 | $1.11M | Sell |
23,939
-887
| -4% | -$43.5K | 0.18% | 68 |
|
|
2025
Q1 | $1.51M | Sell |
24,826
-175
| -0.7% | -$10.2K | 0.27% | 57 |
|
|
2024
Q4 | $1.41M | Hold |
25,001
| – | – | 0.23% | 62 |
|
|
2024
Q3 | $1.29M | Buy |
25,001
+430
| +2% | +$20.2K | 0.21% | 69 |
|
|
2024
Q2 | $1.02M | Buy |
24,571
+16,080
| +189% | +$720K | 0.17% | 68 |
|
|
2024
Q1 | $460K | Sell |
8,491
-30,637
| -78% | -$1.56M | 0.08% | 88 |
|
|
2023
Q4 | $2.01M | Sell |
39,128
-70,782
| -64% | -$3.72M | 0.38% | 53 |
|
|
2023
Q3 | $6.38M | Buy |
109,910
+1,053
| +1% | +$64.5K | 1.35% | 26 |
|
|
2023
Q2 | $6.96M | Sell |
108,857
-2,733
| -2% | -$183K | 1.41% | 23 |
|
|
2023
Q1 | $7.73M | Buy |
111,590
+10,490
| +10% | +$740K | 1.68% | 18 |
|
|
2022
Q4 | $7.27M | Sell |
101,100
-19,170
| -16% | -$1.45M | 1.7% | 21 |
|
|
2022
Q3 | $8.55M | Sell |
120,270
-1,432
| -1% | -$104K | 2.07% | 16 |
|
|
2022
Q2 | $9.37M | Buy |
121,702
+3,152
| +3% | +$240K | 2.09% | 14 |
|
|
2022
Q1 | $8.66M | Sell |
118,550
-14,605
| -11% | -$981K | 1.64% | 21 |
|
|
2021
Q4 | $8.3M | Sell |
133,155
-6,351
| -5% | -$373K | 1.39% | 24 |
|
|
2021
Q3 | $8.26M | Buy |
139,506
+412
| +0.3% | +$27.1K | 1.52% | 24 |
|
|
2021
Q2 | $9.29M | Buy |
139,094
+6,381
| +5% | +$416K | 1.75% | 22 |
|
|
2021
Q1 | $8.38M | Buy |
132,713
+32,472
| +32% | +$2.02M | 1.68% | 22 |
|
|
2020
Q4 | $6.22M | Buy |
100,241
+10,685
| +12% | +$657K | 1.28% | 27 |
|
|
2020
Q3 | $5.4M | Buy |
89,556
+6,397
| +8% | +$385K | 1.16% | 28 |
|
|
2020
Q2 | $4.89M | Hold |
83,159
| – | – | 1.19% | 31 |
|
|
2020
Q1 | $4.63M | Buy |
83,159
+82,159
| +8,216% | +$5.02M | 1.4% | 25 |
|
|
2019
Q4 | $64K | Hold |
1,000
| – | – | 0.02% | 177 |
|
|
2019
Q3 | $51K | Hold |
1,000
| – | – | 0.01% | 191 |
|
|
2019
Q2 | $45K | Hold |
1,000
| – | – | 0.01% | 207 |
|
|
2019
Q1 | $48K | Hold |
1,000
| – | – | 0.01% | 196 |
|
|
2018
Q4 | $52K | Hold |
1,000
| – | – | 0.02% | 178 |
|
|
2018
Q3 | $62K | Hold |
1,000
| – | – | 0.02% | 205 |
|
|
2018
Q2 | $55K | Hold |
1,000
| – | – | 0.02% | 217 |
|
|
2018
Q1 | $63K | Hold |
1,000
| – | – | 0.02% | 206 |
|
|
2017
Q4 | $61K | Hold |
1,000
| – | – | 0.02% | 208 |
|
|
2017
Q3 | $64K | Sell |
1,000
-750
| -43% | -$43.8K | 0.02% | 201 |
|
|
2017
Q2 | $98K | Sell |
1,750
-1,000
| -36% | -$54.4K | 0.03% | 159 |
|
|
2017
Q1 | $150K | Hold |
2,750
| – | – | 0.05% | 132 |
|
|
2016
Q4 | $161K | Sell |
2,750
-200
| -7% | -$10.9K | 0.05% | 131 |
|
|
2016
Q3 | $159K | Hold |
2,950
| – | – | 0.05% | 123 |
|
|
2016
Q2 | $217K | Hold |
2,950
| – | – | 0.07% | 109 |
|
|
2016
Q1 | $188K | Hold |
2,950
| – | – | 0.06% | 111 |
|
|
2015
Q4 | $203K | Buy |
2,950
+750
| +34% | +$49.6K | 0.06% | 110 |
|
|
2015
Q3 | $130K | Hold |
2,200
| – | – | 0.04% | 110 |
|
|
2015
Q2 | $146K | Buy |
+2,200
| New | +$145K | 0.04% | 109 |
|
Other funds holding BMY
VCM
VPM
Arcadia Investment Management's BMY Position: Q1 2026 in Review
Arcadia Investment Management reduced its Bristol-Myers Squibb (BMY) stake by 7.3% in Q1 2026, selling an estimated $122K and leaving 26,704 shares worth $1.62M. The position accounts for 0.28% of the portfolio, ranked #59.
Arcadia Investment Management first reported a position in BMY in Q2 2015 and has held it in 44 quarters since. The position peaked at $9.37M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Arcadia Investment Management held 26,704 shares of Bristol-Myers Squibb worth $1.62M as of Q1 2026.
- Arcadia Investment Management sold 2,090 Bristol-Myers Squibb shares in Q1 2026, an estimated $122K.
- Bristol-Myers Squibb made up 0.28% of Arcadia Investment Management's portfolio in Q1 2026, its #59 holding.
- Arcadia Investment Management first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 44 quarters since.
- Arcadia Investment Management's Bristol-Myers Squibb position peaked at $9.37M in Q2 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Arcadia Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.